鲍曼不动杆菌中脂质A修饰和多粘菌素耐药性所需的一种受PmrB调控的脱乙酰酶
A PmrB-Regulated Deacetylase Required for Lipid A Modification and Polymyxin Resistance in Acinetobacter baumannii.
作者信息
Chin Chui-Yoke, Gregg Kelsey A, Napier Brooke A, Ernst Robert K, Weiss David S
机构信息
Emory Antibiotic Resistance Center, Emory University School of Medicine, Atlanta, Georgia, USA Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, USA Yerkes National Primate Research Center, Emory University School of Medicine, Atlanta, Georgia, USA Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, Maryland, USA.
出版信息
Antimicrob Agents Chemother. 2015 Dec;59(12):7911-4. doi: 10.1128/AAC.00515-15. Epub 2015 Oct 12.
Abstract
Emerging resistance to "last-resort" polymyxin antibiotics in Gram-negative bacteria is a significant threat to public health. We identified the Acinetobacter baumannii NaxD deacetylase as a critical mediator of lipid A modification resulting in polymyxin resistance and demonstrated that naxD is regulated by the sensor kinase PmrB. This represents the first description of a specific PmrB-regulated gene contributing to polymyxin resistance in A. baumannii and highlights NaxD as a putative drug target to reverse polymyxin resistance.
摘要
革兰氏阴性菌对“最后一道防线”多粘菌素类抗生素产生的新耐药性对公众健康构成了重大威胁。我们确定鲍曼不动杆菌NaxD脱乙酰酶是导致多粘菌素耐药性的脂多糖A修饰的关键介质，并证明naxD受传感激酶PmrB调控。这是首次描述鲍曼不动杆菌中一个特定的受PmrB调控的基因对多粘菌素耐药性的作用，并突出了NaxD作为逆转多粘菌素耐药性的潜在药物靶点。
相似文献
1
A PmrB-Regulated Deacetylase Required for Lipid A Modification and Polymyxin Resistance in Acinetobacter baumannii.
Antimicrob Agents Chemother. 2015 Dec;59(12):7911-4. doi: 10.1128/AAC.00515-15. Epub 2015 Oct 12.
2
Multiple Genetic Mutations Associated with Polymyxin Resistance in Acinetobacter baumannii.
Antimicrob Agents Chemother. 2015 Dec;59(12):7899-902. doi: 10.1128/AAC.01884-15. Epub 2015 Oct 5.
3
The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A.
Antimicrob Agents Chemother. 2011 Aug;55(8):3743-51. doi: 10.1128/AAC.00256-11. Epub 2011 Jun 6.
4
Investigation of Novel and Mutations in Isogenic Acinetobacter baumannii Isolates Associated with Colistin Resistance and Increased Virulence .
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.01586-18. Print 2019 Mar.
5
Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens.
Sci Rep. 2016 May 19;6:26233. doi: 10.1038/srep26233.
6
Diversity of polymyxin resistance mechanisms among Acinetobacter baumannii clinical isolates.
Diagn Microbiol Infect Dis. 2017 Jan;87(1):37-44. doi: 10.1016/j.diagmicrobio.2016.10.011. Epub 2016 Oct 8.
7
Genetic alterations in the pmrAB two-component system and lipid A biosynthesis genes of polymyxin-resistant Acinetobacter baumannii isolates.
Acta Microbiol Immunol Hung. 2024 Jun 5;71(2):134-139. doi: 10.1556/030.2024.02268. Print 2024 Jul 2.
8
Analyzing pmrA and pmrB genes in Acinetobacter baumannii resistant to colistin in Shahid Rajai Shiraz, Iran Hospital by PCR: First report in Iran.
Pak J Pharm Sci. 2016 Jul;29(4 Suppl):1401-6.
9
In Vivo Selection of Pan-Drug Resistant Acinetobacter baumannii during Antibiotic Treatment.
Yonsei Med J. 2015 Jul;56(4):928-34. doi: 10.3349/ymj.2015.56.4.928.
10
Molecular Mechanisms of Colistin Resistance Among Pandrug-Resistant Isolates of Acinetobacter baumannii with High Case-Fatality Rate in Intensive Care Unit Patients.
Microb Drug Resist. 2018 Nov;24(9):1271-1276. doi: 10.1089/mdr.2017.0397. Epub 2018 Mar 13.
引用本文的文献
1
Colistin resistance in the era of antimicrobial resistance: challenges and strategic countermeasures.
Folia Microbiol (Praha). 2025 Sep 1. doi: 10.1007/s12223-025-01322-z.
2
Resistance and heteroresistance as a consequence of colistin therapy during murine pneumonia.
bioRxiv. 2025 Jul 24:2025.07.24.666669. doi: 10.1101/2025.07.24.666669.
3
Construction and Characterization of an lpxM-Deficient Strain Using a pyrF/5-FOA Counterselection System.
Infect Drug Resist. 2025 Jun 27;18:3175-3185. doi: 10.2147/IDR.S523844. eCollection 2025.
4
Colistin Resistance Mechanism and Management Strategies of Colistin-Resistant Infections.
Pathogens. 2024 Nov 28;13(12):1049. doi: 10.3390/pathogens13121049.
5
Molecular Mechanisms of Bacterial Resistance to Antimicrobial Peptides in the Modern Era: An Updated Review.
Microorganisms. 2024 Jun 21;12(7):1259. doi: 10.3390/microorganisms12071259.
6
Treatment Strategies of Colistin Resistance Infections.
Antibiotics (Basel). 2024 May 6;13(5):423. doi: 10.3390/antibiotics13050423.
7
PmrAB, the two-component system of , controls the phosphoethanolamine modification of lipooligosaccharide in response to metal ions.
J Bacteriol. 2024 May 23;206(5):e0043523. doi: 10.1128/jb.00435-23. Epub 2024 Apr 25.
8
Mechanistic and biophysical characterization of polymyxin resistance response regulator PmrA in .
Front Microbiol. 2024 Feb 27;15:1293990. doi: 10.3389/fmicb.2024.1293990. eCollection 2024.
9
: an evolving and cunning opponent.
Front Microbiol. 2024 Jan 22;15:1332108. doi: 10.3389/fmicb.2024.1332108. eCollection 2024.
10
Disrupting iron homeostasis can potentiate colistin activity and overcome colistin resistance mechanisms in Gram-Negative Bacteria.
Commun Biol. 2023 Sep 13;6(1):937. doi: 10.1038/s42003-023-05302-2.
本文引用的文献
1
Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria.
Front Microbiol. 2014 Nov 26;5:643. doi: 10.3389/fmicb.2014.00643. eCollection 2014.
2
Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii.
Antimicrob Agents Chemother. 2013 Oct;57(10):4831-40. doi: 10.1128/AAC.00865-13. Epub 2013 Jul 22.
3
NaxD is a deacetylase required for lipid A modification and Francisella pathogenesis.
Mol Microbiol. 2012 Nov;86(3):611-27. doi: 10.1111/mmi.12004. Epub 2012 Sep 11.
4
Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.
J Antimicrob Chemother. 2012 Jul;67(7):1607-15. doi: 10.1093/jac/dks084. Epub 2012 Mar 22.
5
The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A.
Antimicrob Agents Chemother. 2011 Aug;55(8):3743-51. doi: 10.1128/AAC.00256-11. Epub 2011 Jun 6.
6
Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system.
Antimicrob Agents Chemother. 2011 Jul;55(7):3370-9. doi: 10.1128/AAC.00079-11. Epub 2011 May 16.
7
Resistance status and evolution trends of Klebsiella pneumoniae isolates in a university hospital in Greece: ineffectiveness of carbapenems and increasing resistance to colistin.
Chemotherapy. 2010;56(6):448-52. doi: 10.1159/000320943. Epub 2010 Nov 18.
8
Polymyxins and their novel derivatives.
Curr Opin Microbiol. 2010 Oct;13(5):574-81. doi: 10.1016/j.mib.2010.09.002. Epub 2010 Sep 24.
9
Resistance to polymyxins: Mechanisms, frequency and treatment options.
Drug Resist Updat. 2010 Aug-Oct;13(4-5):132-8. doi: 10.1016/j.drup.2010.05.002. Epub 2010 Jun 17.
10
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
Antimicrob Agents Chemother. 2009 Sep;53(9):3628-34. doi: 10.1128/AAC.00284-09. Epub 2009 Jun 15.
Zotero 插件